316-69-8

Basic information

• Product Name: 4-FLUORONAPHTHALENE-1-SULFONYL CHLORIDE
• Synonyms: 4-FLUORONAPHTHALENE-1-SULFONYL CHLORIDE;4-FLUORONAPHTHALENE-1-SULPHONYL CHLORIDE;BUTTPARK 27\09-01;1-(Chlorosulphonyl)-4-fluoronaphthalene;4-Fluoronaphthalene-1-sulphonylchloride97%
• CAS NO: 316-69-8
• Molecular Formula: C₁₀H₆ClFO₂S
• Molecular Weight: 244.67
• Mol File: 316-69-8.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 352.5±17.0 °C(Predicted)
• Appearance: /
• Density: 1.488±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-FLUORONAPHTHALENE-1-SULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-FLUORONAPHTHALENE-1-SULFONYL CHLORIDE(316-69-8)
• EPA Substance Registry System: 4-FLUORONAPHTHALENE-1-SULFONYL CHLORIDE(316-69-8)

Safety Data

• Hazard Codes: C
• Hazardous Substances Data: 316-69-8(Hazardous Substances Data)

Usage

General Description

4-Fluoronaphthalene-1-sulfonyl chloride is a chemical compound with the molecular formula C10H6ClFO2S. It is a sulfonic acid derivative with a chlorine atom and a fluorine atom attached to a naphthalene ring. 4-FLUORONAPHTHALENE-1-SULFONYL CHLORIDE is used in organic synthesis as a reagent for introducing the sulfonyl chloride functional group into other molecules. It is also used in the pharmaceutical industry as a building block in the synthesis of various pharmaceutical compounds. Additionally, it has applications in the field of materials science, particularly in the development of new polymers and organic materials. 4-Fluoronaphthalene-1-sulfonyl chloride is known for its reactivity and is handled with care due to its potential for causing skin and eye irritation.

Upstream product

• 321-38-0 1-Fluoronaphthalene 

Downstream Products

• 571-54-0 4-fluoro-N-phenylnaphthalene-1-sulfonamide 
• 782445-10-7 N-phenyl-4-(piperazin-1-yl)naphthalene-1-sulfonamide 
• 59080-18-1 1-Fluoro-4-naphthylmethylsulfon 
• 594853-76-6 1-fluoro-4-(phenylsulfonyl)naphthalene 

Relevant articles and documents

From hit to lead: Structure-based discovery of naphthalene-1-sulfonamide derivatives as potent and selective inhibitors of fatty acid binding protein 4

Fatty acid binding protein 4 (FABP4) plays a critical role in metabolism and inflammatory processes and therefore is a potential therapeutic target for immunometabolic diseases such as diabetes and atherosclerosis. Herein, we reported the identification of naphthalene-1-sulfonamide derivatives as novel, potent and selective FABP4 inhibitors by applying a structure-based design strategy. The binding affinities of compounds 16dk, 16do and 16du to FABP4, at the molecular level, are equivalent to or even better than that of BMS309403. The X-ray crystallography complemented by the isothermal titration calorimetry studies revealed the binding mode of this series of inhibitors and the pivotal network of ordered water molecules in the binding pocket of FABP4. Moreover, compounds 16dk and 16do showed good metabolic stabilities in liver microsomes. Further extensive in vivo study demonstrated that 16dk and 16do exhibited a dramatic improvement in glucose and lipid metabolism, by decreasing fasting blood glucose and serum lipid levels, enhancing insulin sensitivity, and ameliorating hepatic steatosis in obese diabetic (db/db) mice.

Substituted Disulfonamide Compounds

Substituted disulfonamide compounds corresponding to formula I: In which R1, R2, R3, R4a, R4b, R5a, R5b, R8, R9a, R9b, R10, R11, a, b, s, t and A have defined meanings, pharmaceutical compositions containing one or more such compounds, processes for preparing such compounds, and a method of using such compounds for the treatment or inhibition of pain and/or other conditions mediated by the bradykinin receptor 1 (BR1).

GLYT1 TRANSPORTER INHIBITORS

The invention provides a compound of formula (I): or a salt, solvate or a physiologically functional derivative thereof, wherein R1 to R10 are as defined in the specification and uses of such compounds. The compounds inhibit GlyT1 transporters and are useful in the treatment of certain neurological and neuropsychiatric disorders, including schizophrenia.